Acrux Dds Pty Ltd

Beijing University of Technology

Acrux Dds Pty Ltc.

Barrie Charles Finnin

Timothy Matthias Morgan

Barry Leonard Reed

Kathryn Traci-Jane Klose

Nina Wilkins

Margarita Vladislavova Bakalova

Nora Yat Knork Chew

Kathryn Taci-Jane Klose

Ennio La Guardia

Ngan Thi Kim Tran

Timothy Matthias Morgon

Karthryn Traci-Jane Klose

Felicia Maria Colagrande

Jianwen Zhou

Barry Lenard Reed

Nina Frances Wilkins

A pharmaceutical composition for transdermal delivery comprising

Transdermal delivery rate control using amorphous pharmaceutical compositions

The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.

Dermal penetration enhancers and drug delivery systems involving the same

Dermal penetration enhancers and drug delivery systems involving same

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic or locally acting non-steroidal anti-inflammatory drug to an animal which comprises applying an effective amount of the non-steroidal anti-inflammatory drug in the form of the drug delivery system of the present invention.

Transdermal delivery of non-steroidal anti-inflammatory drugs

The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.

Topical delivery of antifungal agents

The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.

Topical delivery of anti-alopecia agents

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antianxiety agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antianxiety agent to an animal which comprises applying an effective amount of the antianxiety agent in the form of the drug delivery system of the present invention.

Transdermal delivery of antianxiety agents

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.

Transdermal delivery of antiparkinson agents

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention

Transdermal delivery of hormones

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.

Transdermal delivery of analgesics

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.

Transdermal delivery of antiemetics

A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.

Growing community of inventors

Glen Iris, Australia

Barrie Charles Finnin